(Reuters) -The Canadian province of Alberta reported its first death of a affected person from a uncommon blood clot situation after receiving the AstraZeneca (NASDAQ:) COVID-19 vaccine, its chief medical officer confirmed late Tuesday.
The Alberta case marks the second case of blood clots, and the one death after greater than 253,000 doses of AstraZeneca had been administered within the province, the assertion added.
AstraZeneca didn’t instantly reply to Reuters’ request for a remark.
Last month, the province of Quebec reported Canada’s first death of a affected person after receiving the AstraZeneca COVID-19 vaccine.
The uncommon complication, which some regulators together with Health Canada are calling Vaccine-Induced Prothrombotic Immune Thrombocytopenia, includes blood clots accompanied by a low rely of platelets, cells within the blood that assist it to clot.
Fusion Media or anybody concerned with Fusion Media is not going to settle for any legal responsibility for loss or harm because of reliance on the data together with knowledge, quotes, charts and purchase/promote indicators contained inside this website. Please be absolutely knowledgeable concerning the dangers and prices related to buying and selling the monetary markets, it is without doubt one of the riskiest funding types attainable.